Gilead Sciences Partners with Gritstone Oncology for HIV Cure

Gilead Sciences and Gritstone Oncology have teamed up to develop a vaccine-based immunotherapy to cure HIV infection.

Under the agreement, the companies will leverage Gritstone’s vaccine platform, which uses both messenger-RNA and adenovirus-based vectors, as well as antigens produced by Gilead, which will be spearheading a phase 1 study of the HIV therapeutic vaccine candidate.

Gritstone will receive $60 million upfront and is eligible to receive up to $725 million based on reaching certain development and sales-based milestones and future royalties.